Table 2.
Multivariate analysis of overall survival in the validation cohort.
| Characteristic | HRa | 95% CIa | P-value |
|---|---|---|---|
| Age | 0.98 | 0.96–1.01 | 0.13 |
| WHO Performance status | |||
| 0 | Ref | ||
| 1–2 | 1.88 | 1.27, 2.80 | 0.002 |
| ctDNA | |||
| ctDNA negative | Ref | ||
| ctDNA positive | 1.62 | 1.05, 2.50 | 0.029 |
| CA19.9_median | |||
| ≤1366 | ref | ||
| >1366 | 1.70 | 1.17, 2.49 | 0.006 |
| NLRc | |||
| <3.2 | ref | ||
| ≥3.2 | 1.08 | 0.73, 1.60 | 0.7 |
Bold values indicate statistical significance p < 0.05.
Analysis was performed after stratification on studies and centers.
aHR Hazard ratio.
bCI confidence interval.
cNLR neutrophils lymphocytes ratio.